新京报讯（记者张秀兰）1月5日，全球首个且目前唯一突破性疗法激活素信号传导抑制剂（ASI）欣瑞来（注射用索特西普）获国家药监局批准，适用于治疗世界卫生组织（WHO）功能分级（FC）Ⅱ-Ⅲ级的肺动脉高压（PAH，WHO第1组）成年患者，以改善患者的运动能力和WHO功能分级。 PAH是一种相对少见、治疗棘手的心血管疾病，研究提示，不进行针对性治疗的特发性PAH患者出现症状后的中位生存期仅2.8 年。...
Source Link新京报讯（记者张秀兰）1月5日，全球首个且目前唯一突破性疗法激活素信号传导抑制剂（ASI）欣瑞来（注射用索特西普）获国家药监局批准，适用于治疗世界卫生组织（WHO）功能分级（FC）Ⅱ-Ⅲ级的肺动脉高压（PAH，WHO第1组）成年患者，以改善患者的运动能力和WHO功能分级。 PAH是一种相对少见、治疗棘手的心血管疾病，研究提示，不进行针对性治疗的特发性PAH患者出现症状后的中位生存期仅2.8 年。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.